Ortiz-Maldonado V, Presa M, Tejado N, Pardo C, Martín-Escudero V, Oyagüez I, Martín A
Axicabtagene Ciloleucel As Second-Line Treatment For Relapsed/ Refractory Large B-Cell Lymphoma In Spain: A Cost-Effectiveness Analysis Refractory Large B-Cell Lymphoma In Spain: A Cost-Effectiveness Analysis
26th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 12-15 nov 2023
Peral C, de Lossada Juste A, Lwoff N, Espinoza Cámac N, Martínez-Martínez N, Casado MÁ, Burke T, Kane A, Alvir J, Thakkar S, Ferri Grazzi E
Economic Burden of Moderate and Severe Hemophilia A and B in Spain, Real-World Evidence Insights from the Cost of Hemophilia in Europe: A Socio-Economic Survey II (CHESS II) Study
26th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 12-15 nov 2023
Parramon M, Juárez M, de Pedro S, Echave M, Oyagüez I, Casado MÁ, Martínez-Salamanca JI
Cost Analysis of Prostav®: A New Telomere-Based Biomarker for the Early Detection of Prostate Cancer Available in Europe
26th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 12-15 nov 2023
Córdoba R, López-Corral L, Presa M, Martín-Escudero V, Casado MÁ, Pardo C
Value of Axicabtagene Ciloleucel Versus Chemotherapy in the Large B-Cell Lymphoma Treatment: Health Outcomes Based on the Number of Patients Treated in Spain
25th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Viena (Austria). 06-09 nov 2022
Presa M, Vicente D, Calles A, Salinas-Ortega L, Naik J, García LF, Soto J
Lorlatinib as a first-line treatment for ALK+ advanced Non-Small Cell Lung Cancer: a cost-effectiveness analysis in Spain
25th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Viena (Austria). 06-09 nov 2022
Bastos-Oreiro M, de las Heras A, Presa M, Casado MA, Pardo C, Martín-Escudero V, Sureda A
Axicabtagene ciloleucel and tisagenlecleucel for the treatment of relapsed/refractory diffuse large B-cell lymphoma in Spain: a cost-effectiveness analysis
24th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Virtual. 30 nov-3 dic 2021
Muñoz A, Gomez-Peralta F, Mareque M, Maderuelo M, Casado MA
Patient preferences for diabetes management in Spain – A Discrete Choice Experiment
24th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Virtual. 30 nov-3 dic 2021
de Andrés-Nogales F, Cruz E, Calleja MÁ, Delgado O, Gorgas -Torner MQ, Espin J, Mestre-Ferrandiz J, Palau F, Ancochea A, Arce R, Domínguez-Hernández R, Casado MA, FinMHU-MCDA Group
A Multi-Stakeholder Multicriteria Decision Analysis in Rare Diseases: Reimbursement Criteria for Orphan Drugs in Spain (FinMHU-MCDA study)
23rd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Virtual. 16-19 nov 2020
Ferrando R , Echave M , Espinoza Cámac N , Maratia S , Casado MA